{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.9","upperLimit":"8.6","value":"6.5"},{"groupId":"OG001","lowerLimit":"3.6","upperLimit":"12.6","value":"7.3"},{"groupId":"OG002","lowerLimit":"1.3","upperLimit":"15.0","value":"8.3"},{"groupId":"OG003","lowerLimit":"2.8","upperLimit":"5.9","value":"4.5"}]}],"title":"Duration of intracranial"},{"categories":[{"measurements":[{"comment":"Upper Limit not reachable.","groupId":"OG000","lowerLimit":"5.8","upperLimit":"NA","value":"10.2"},{"comment":"Lower and upper Limit not reachable.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"3.0","upperLimit":"22.4","value":"4.9"},{"comment":"Upper Limit not reachable.","groupId":"OG003","lowerLimit":"1.8","upperLimit":"NA","value":"5.9"}]}],"title":"Duration of extracranial"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.9","upperLimit":"8.3","value":"6.2"},{"comment":"Upper Limit not reachable.","groupId":"OG001","lowerLimit":"5.3","upperLimit":"NA","value":"12.5"},{"groupId":"OG002","lowerLimit":"1.3","upperLimit":"16.3","value":"6.6"},{"groupId":"OG003","lowerLimit":"2.8","upperLimit":"11.2","value":"4.5"}]}],"title":"Duration of Overall Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"17"}],"units":"Participants"}],"description":"Duration of intracranial, extracranial and overall response, are defined as the time from first documented evidence of CR or PR until time of first documented intracranial, extracranial, or overall disease progression. No hypothesis testing completed for cohort A,B,C and D","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.","id":"OG000","title":"Cohort A"},{"description":"Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity","id":"OG001","title":"Cohort B"},{"description":"Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity","id":"OG002","title":"Cohort C"},{"description":"Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity","id":"OG003","title":"Cohort D"}],"paramType":"MEDIAN","populationDescription":"All Treated population - All subjects who receive at least one dose of study medication are comprised the All Treated subjects (ATS) population","reportingStatus":"POSTED","timeFrame":"From first documented evidence of CR or PR until time of first documented intracranial, extracranial, or overall disease progression","title":"Duration of Intracranial, Extracranial and Overall Response for Each Cohort","type":"SECONDARY","unitOfMeasure":"Month"}